APOE and Alzheimer disease: Similarly, for AD, an antibody specifically targeting aggregated forms of the AD-risk variant APOE4 was administered to APOE4/APPPS1 double-humanised mice and shown to reduce amyloid beta deposition, implicating APOE4 aggregation in the formation of amyloid plaques (Liao et al. 2018).